Cipla trades higher on the bourses

21 Feb 2013 Evaluate

Cipla is currently trading at Rs. 384.30, up by 2.45 points or 0.64% from its previous closing of Rs. 381.85 on the BSE.

The scrip opened at Rs. 381.00 and has touched a high and low of Rs. 384.40 and Rs. 381.00 respectively. So far 1,91,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 435.00 on 09-Jan-2013 and a 52 week low of Rs. 286.50 on 26-Mar-2012.

The current market cap of the company is Rs. 30,856.00 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.08% and 28.50% respectively.

The patent office has again ruled in favor of Cipla, reinstating its earlier decision to revoke the American company’s patent for cancer drug Sutent in India. Following a post-grant opposition by Cipla in October last year, the patent controller had rejected Pfizer’s claim for the patent over Sutent.

After the apex court sent the issue back to the patent controller, the multinational company approached the Delhi High Court seeking a stay on Cipla selling the drug. In December 2012, the court adjourned the case filed by Pfizer and decided to wait for the patent controller’s decision.

Pfizer granted a patent for Sutent in India in 2007, launched the drug at a price of Rs 1.96 lakh for a 45-day treatment. Cipla’s version of the drug is reportedly priced at almost one-fourth of the cost. The battle over patents on medicines in India has heated up recently after the patent office revoked patents of various drugs.

Cipla Share Price

1497.45 -23.10 (-1.52%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×